Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242720 | 0.74 | ALDH1A1 (0.40) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL1735150 | 0.74 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL9122124 | 0.72 | ALDH1A1 (0.36) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL14465627 | 0.71 | GPBAR1 (0.38) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL5291180 | 0.69 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL12285479 | 0.69 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL2280554 | 0.68 | SMN1; SMN2 (0.65) | SMN1; SMN2HTTNPSR1 | |
| SCHEMBL19389589 | 0.68 | LMNA (0.44) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL16960385 | 0.67 | ALDH1A1 (0.41) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL23067899 | 0.65 | ALDH1A1 (0.41) | ALDH1A1CYP3A4TSHRMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759584-B2 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | BAYER CROPSCIENCE AG (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2231679-B1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2070934-A1 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | Bayer CropScience AG (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | ATIC, SRM, F12 | ALDH1A1 1910/4885CYP3A4 3446/4885TSHR 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.